There has been substantial investor interest in RLF-100 and its potential to treat not only COVID-19, but also Acute Respiratory Distress Syndrome related to sepsis, sarcoid lung disease, and other life-threatening pulmonary conditions.
You can find below a preprint providing insight into the mechanisms that underlie RLF-100 (Aviptadil). You may also want to watch some of the TV news stories that have aired about RLF-100.
NeuroRx is a private-held US company that is partnering with Relief in the development of RLF-100 and is also developing NRX-101 for the treatment of suicidal depression. If you would like to learn more about NeuroRx, please contact email@example.com
The stock of Relief Therapeutics Holdings (SIX:RLF, OTC:RLFTF) trades on the Swiss Exchange and the US OTC exchange.